This site is intended for healthcare professionals only
LoginRegister

Psychiatry Dialogues

FDA Approves Milsaperidone as First-Line Treatment for Schizophrenia and Bipolar I Disorder

FDA Approves Milsaperidone as First-Line Treatment for Schizophrenia and Bipolar I Disorder

The U.S. Food and Drug Administration has approved milsaperidone (Bysanti) tablets as a first-line therapy for adults with schizophrenia and manic or...
View All

Latest News and Guidelines

Investigational TSND-201 Shows Early and Significant Efficacy in Severe PTSD in Phase II Trial

Investigational TSND-201 Shows Early and Significant Efficacy in Severe PTSD in Phase II Trial

Peripheral Retina Changes Could Signal Early Alzheimers, Research Finds

Peripheral Retina Changes Could Signal Early Alzheimer's, Research Finds

Adolescent cannabis use linked to doubling risk of psychotic and bipolar disorders: JAMA

Adolescent cannabis use linked to doubling risk of psychotic and bipolar disorders: JAMA

PG Medical Student Found Dead in DIMHANS Hostel in Dharwad.

ICMR-Led Multistate Study to Roll Out Structured Suicide Prevention Model in Indian Campuses

Exercise Combined with Protein Drinks Enhances Function in Dementia Patients, Study Finds

Exercise Combined with Protein Drinks Enhances Function in Dementia Patients, Study Finds

Two Weeks of Lavender Tea Linked to Improved Mental Health in Misophonia Patients: RCT Suggests

Two Weeks of Lavender Tea Linked to Improved Mental Health in Misophonia Patients: RCT Suggests

View All
X